1022112-32-8

Basic information

• Product Name: ethyl 2-(2,3-difluoro-6-nitrophenyl)-3-oxobutanoate
• Synonyms: ethyl 2-(2,3-difluoro-6-nitrophenyl)-3-oxobutanoate;ETHYL 2-(2,3-DIFLUORO-6-NITROPHENYL)-3-OXOBUTANOATE(WXG02898)
• CAS NO: 1022112-32-8
• Molecular Formula: C₁₂H₁₁F₂NO₅
• Molecular Weight: 287.22
• Mol File: 1022112-32-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 375.0±37.0 °C(Predicted)
• Appearance: /
• Density: 1.368±0.06 g/cm3(Predicted)
• PKA: 7.11±0.46(Predicted)
• CAS DataBase Reference: ethyl 2-(2,3-difluoro-6-nitrophenyl)-3-oxobutanoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-(2,3-difluoro-6-nitrophenyl)-3-oxobutanoate(1022112-32-8)
• EPA Substance Registry System: ethyl 2-(2,3-difluoro-6-nitrophenyl)-3-oxobutanoate(1022112-32-8)

Safety Data

• Hazardous Substances Data: 1022112-32-8(Hazardous Substances Data)

Upstream product

• 771-69-7 2,3,4-trifluoronitrobenzene 
• 141-97-9 ethyl acetoacetate 

Downstream Products

• 1022112-33-9 ethyl 2-(2-fluoro-3-hydroxy-6-nitrophenyl)-3-oxobutanoate 
• 288385-93-3 2-methyl-4-fluoro-5-methoxy-1H-indole 

Relevant articles and documents

Design, synthesis and biological evaluation of O-linked indoles as VEGFR-2 kinase inhibitors (I)

Inhibition of VEGFR-2 signaling pathway has already become one of the most promising approaches for the treatment of cancer. In this study, we describe the design, synthesis, and biological evaluation of a series of O-linked indoles as potent inhibitors of VEGFR-2. Among these compounds, 18 showed significant anti-angiogenesis activities via VEGFR-2 in enzymatic proliferation assays, with IC50 value of 3.8 nmol/L. Kinase selectivity profiling revealed that 18 was a multitargeted inhibitor, and it also exhibited good potency against VEGFR-1, PDGFR-α and β.

Commercial synthesis of a pyrrolotriazine-fluoroindole intermediate to brivanib alaninate: Process development directed toward impurity control

The development of a practical, commercial process for the preparation of 4-fluoro-2-methyl-indol-5-ol and its subsequent coupling with a pyrrolotriazine to form an advanced intermediate of the oncology therapy brivanib alaninate is described. A key aspect is the multikilogram-scale preparation of the fluoroindole intermediate from trifluoronitrobenzene and the subsequent coupling while achieving impurity minimalization. As brivanib alaninate is a high-dose drug, the synthesis of highquality API with low levels of impurities is critical.

CHEMICAL PROCESS

The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline.